Introduction
Chronic myelomonocytic leukaemia (CMML) is a clonal disorder of haematopoietic stem cells and is characterized by the presence of peripheral blood monocytosis and features of BM dysplasia, but with fewer than 20% blasts in the BM. It carries a relatively poor prognosis with a median survival of 20-40 months with transformation to AML occurring in up to one-third of patients. 1 Treatment is composed mainly of supportive care, cytoreductive therapy or intensive chemotherapy. 2 Haematopoietic SCT (HSCT) offers the only potentially curative option in CMML, but data regarding outcomes are limited. This is partly because of the relatively low numbers of patients with CMML who are eligible for transplantation but additionally, outcomes in this group of patients are frequently reported within a heterogeneous patient group including those with myelodysplasia and/or myeloproliferative disorders. 3 Previously, myeloablative conditioning regimens were used in this setting, but this has been reported as being associated with high non-relapse mortality (NRM). 4 Increasingly, however, those patients who would have been deemed ineligible for a standard, myeloblative allogeneic transplant may now be considered suitable for reduced-intensity conditioning (RIC) transplantation. RIC regimens have been successfully used to treat patients with high-risk myelodysplastic syndromes and AML. 5, 6 In this study, we report on the single-centre results of 18 CMML patients who have undergone allogeneic HSCT. The pre-transplant characteristics of these patients and outcomes after receipt of allogeneic stem cells are evaluated below.
Materials and methods

Patient demographics
Between 1998 and 2007, 18 patients who were diagnosed with CMML according to the World Health Organization classification 1 underwent allogeneic transplantation at King's College Hospital and were included in the analysis (Table 1 summarizes patient demographics). Data on seven patients have been previously reported and are updated and included in this analysis. 6 The median age of patients was 54 years (range: 38-66 years), and the median follow-up was 488 days (range: 39-1760 days). In all, 11 patients had an abnormal karyotype, and of these, 4 had complex/ multiple cytogenetic abnormalities. Splenectomy was performed in one patient before transplant. The median interval from diagnosis to transplant was 21 months (range: 4-84 months). Seven patients had AML, which had transformed from CMML. A total of 17 patients had received chemotherapy before transplant (range of courses: 1-3); information was unavailable for 1 patient. Most patients received fludarabine, arabinoside cytarabine, granulocyte colony-stimulating factor-based regimen, with or without the addition of idarubicin (FLAG or FLAGIda). Two patients had received preceding autologous SCTs (see Table 2 for details). Before transplantation, disease status was reassessed by BM examination. Eight patients had o5% blasts in their BM at transplantation; nine were in CMML-1 with 5-9% blasts and one patient had refractory disease with 23% blasts in the BM.
All donor-recipient pairs were matched for HLA-A, -B, -C, -DRB1 and DQB1 by high-resolution allelic testing. Seven patients had a matched sibling donor available to them; eight patients (61%) had a 10/10 HLA-matched unrelated donor, and a further three patients had a 1 HLAlocus mismatch (two at the A locus and one at DQB1).
Transplantation protocols
A total of 15 patients received a fludarabine/BU-based RIC HSCT, of these 13 received T-cell depletion using alemtuzumab and 2 with ATG (anti-thymocyte globulin). The FBC (fludarabine, BU, CAMPATH) protocol consisted of fludarabine (30 mg/m 2 i.v. for 5 days), BU (3.2 mg/ kg i.v. in four divided doses daily for 2 days) and alemtuzumab (20 mg daily for 5 days). In the FBATG (fludarabine, BU, anti-thymocyte globulin) protocol, patients were administered i.v. thymoglobulin (ATGGenzyme) (total dose 6 mg/kg i.v. over 4 days). Two patients received an augmented dose BU FBC regimen (BU 3.2 mg/kg i.v. in four divided doses daily for 4 days) due to residual disease. One patient received a myeloablative Bu/ Cy allograft, comprising BU (3.2 mg/kg i.v. daily for 4 days) and cyclophosphamide (50 mg/kg i.v. daily for 4 days) (individual conditioning regimen details are summarized in Table 2 ).
Unselected PBPCs or BM stem cells were infused on day 0. The source of stem cells was peripheral blood (mobilized by granulocyte colony-stimulating factor) in two-thirds of patients and BM in one-third. Post-transplant GVHD prophylaxis was achieved with CYA (1.5 mg/kg i.v. every 12 h) from day À1 titrated to plasma trough levels of 150-200 ng/l. Oral CYA was substituted when a good oral intake was achieved, and rapidly tapered from day þ 56 in the absence of GVHD. All neutropenic patients received standard nursing and supportive care protocols patients as described previously. 6 Donor engraftment was defined as the first of 3 consecutive days after transplant at which the neutrophil count was sustained above 0.5 Â 10 9 per l and plts were maintained above 20 Â 10 9 per l (without transfusion support). Chimerism was assessed in donor-recipient sex mismatches, using X, Y-FISH and/or PCR and fluorescent analysis of STR sequences on BM, whole blood and peripheral CD3 þ and CD15 þ cell fractions using the Promega PowerPlex 16 System (Promega, Madison, WI, USA). 7 Chimerism assessments were scheduled for days 28, 56 and 100, 6 months and then yearly. Graded incremental donor lymphocyte infusions (DLIs) were administered if, after day 100, there was evidence of decreasing donor chimerism despite full withdrawal of immunosuppression. DLIs were also administered in the presence of persisting or progressive disease after withdrawal of immunosuppression. Both acute and chronic GVHD were assessed and graded using standard criteria. 8, 9 Statistical analysis OS was measured from day 0 to death from any cause or last-known follow-up; disease-free survival from day 0 to Table 1 Characteristics of CMML patients undergoing allogeneic transplantation
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No. of patients (n ¼ 18) Allogeneic HSCT for CMML P Krishnamurthy et al the first indicator of relapse (morphological or cytogenetic), death from any cause or last-known follow-up. Survival curves were estimated using the Kaplan-Meier methodology, and log-rank test was used to assess differences between groups. Categorical variables were compared using the w 2 -test, and continuous variables were compared using the Mann-Whitney test. Univariate comparisons were performed using the Cox proportional hazards regression model. All analyses were performed using SPSS version 14.0. (SPSS) and Microsoft Excel 2000 (Microsoft).
Results
Engraftment and chimerism
The median number of days until neutrophil and plt regeneration was 17 (range: 12-35 days) and 19 (range: 10-37 days), respectively. All patients achieved sustained neutrophil regeneration, but two patients failed to maintain a plt count 420 Â 10 9 per l persistently after transplant because of splenomegaly, with one patient requiring splenectomy after transplant.
BM and peripheral blood chimerism was evaluable for 10 patients at day 100, with 5 patients attaining full donor (495%) chimerism in BM and peripheral blood (CD3 and CD15) lineages, whereas 5 patients had mixed donor (5-95%) chimerism.
Overall outcomes
The actuarial 3-year OS, NRM and relapse incidence for the cohort was 31±11%, 31±14% and 47±13%, respectively ( Figure 1 ). The median time from diagnosis to transplantation was 17 months (range: 6-25 months) in those who remained alive at follow-up (6 patients) and 25 months (range: 4-84 months) in those who had died (12 patients). It is notable that each of these six patients had normal cytogenetics at presentation. Patients with favourable cytogenetics, as defined by the IPSS (International Prognostic Scoring System), 10 had a 3-year disease-free survival of 65 ± 17%, whereas none of the seven patients with intermediate or poor risk cytogenetics survived beyond 2 years (Po0.01) (Figure 2a ). No patients with favourable risk cytogenetics died from NRM causes, while the 2-year NRM for intermediate/poor risk cytogenetics subgroup was 71 ± 22% (Po0.02) (Figure 2b) .
In terms of disease status at transplantation, patients who had o5% BM blasts had a 3-year estimated disease-free survival of 46.9±19%, when compared with those with 45% blasts at the time of transplantation (that is, 20.0 ± 13% (P ¼ 0.33, Figure 2c ). Out of the 10 patients with 45% blasts at the time of transplant, only 2 were alive at follow-up. Three patients within this subgroup had been treated with either a moderately intensive protocol or myeloablative regimen, with two patients dying of transplant-related complications, and one (with 23% blasts at the time of transplant) from early disease relapse after transplant. Recipient age, type of conditioning regimen or stem cell dose did not have a significant impact on overall outcomes.
Relapse and TRM Overall, 12 patients had died at the time of last follow-up. Eight patients (44%) showed evidence of relapsed CMML or AML after transplant (median time to relapse was 200 days, range: 34-349 days) and all eventually died from disease relapse at a median of 39 days after HSCT (range: 5-86 days). The cause of TRM was GVHD in two patients, and infections in another two (respiratory syncitial virus in one patient and bacterial sepsis with acute respiratory distress syndrome in another patient). CMV reactivation occurred in six patients after transplant at a median of 45 days after transplant (range: 24-60 days). None of these patients died due to CMV reactivation.
Donor lymphocyte infusions
Six patients (33%) received DLI at a median of 232 days (range: 177-1095 days) after transplant (four patients received one dose of DLI, two patients received three doses of DLI). Indications for DLI were falling donor CD3 þ chimerism in four patients, and morphological relapse in two patients. In the four patients with falling donor CD3 þ chimerism, two progressed to morphological relapse despite receiving pre-emptive DLI. Of the other two patients, both received three doses of DLI (cumulative dose of 6.5 Â 10 6 CD3 þ cells per kg); both patients achieved stable mixed CD3 þ chimerism after DLI and remain alive (at 1760 and 1430 days after HSCT). Two patients were treated with DLI for morphological relapse at 180 days and 349 days after transplant, respectively; both patients failed to respond to DLI and died within 2 months.
Graft-versus-host disease
A total of eight patients (44%) developed acute GVHD (six patients with cutaneous, one with gut, one with cutaneous and gut). Acute GVHD occurred at a median of 65 days after transplant (range: 28-89 days). Five patients developed grade I-II acute GVHD with three patients documented as having grade III-IV GVHD. One patient died after developing acute GVHD of the gut (grade III/IV colitis) at 89 days. A further three patients developed chronic GVHD. Two patients were documented as having chronic sclerodermatous GVHD of the skin, with a further patient having biopsy-proven liver GVHD. It is noteworthy that five out of the six long-term surviving patients in this study had GVHD (either acute or chronic).
Discussion
In a group of heavily pre-treated older patients, (most of whom received RIC incorporating T-cell depletion), with less than half of the patients in CR at the time of transplant, the 3-year OS for our cohort was a favourable 31% with a NRM of 31%. However, we observed a high relapse incidence of 47% at 3 years, which was the main limitation of our approach. The small size of our cohort limits any detailed analysis of predictive factors influencing outcomes, although there was a suggestion that patients with 45% blasts at the time of transplantation, and those who did not develop GVHD were more likely to undergo disease relapse.
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Cum survival Figure 1 Kaplan-Meier curves depicting (a) OS, (b) disease-free survival, (c) TRM and (d) relapse incidence for all 18 patients with CMML.
Allogeneic HSCT for CMML P Krishnamurthy et al observed to be associated with a high NRM of 41-52%. 4, 11 An EBMT (European Group for Blood and Marrow Transplantation) registry analysis of 50 adult patients allografted for CMML, in which 38 patients received matched sibling allografts and just over half of the patients were in CR at the time of transplantation, reported that 26 patients (52%) died because of non-relapse causes (mainly GVHD) and the 2-year estimated relapse incidence was 42%. 4 There was a reduction in relapse incidence in those who developed acute GVHD, and a higher rate of relapse incidence in patients receiving T-cell depletion, suggesting the existence of a graft-versus-CMML effect. In addition, it was noted that adverse cytogenetics were associated with a shortened survival, as was observed in our study.
All but one of the patients in our cohort had previous intensive chemotherapy; in particular, seven patients had CMML, which had transformed to AML, which required aggressive treatment before transplantation. It remains unclear as to what is the optimum timing for allografting in CMML, and it is possible that transplantation of certain patients upfront, rather than following chemotherapy would be a more appropriate option, potentially serving to reduce overall treatment-related morbidity and mortality. Ocheni et al. 12 have recently reported on the outcomes of 12 patients allografted using either a moderately intensive fludarabin/amsacrin protocol or a myeloablative conditioning. The majority of patients had not received any previous intensive chemotherapy. Although the follow-up was limited at 26 months, the outcomes were promising with a relapse incidence, disease-free and OS of 17, 50 and 75%, respectively. This study highlights the role of dose intensity in disease control after allogeneic HSCT for CMML. Recent concurrent improvements in conditioning regimens may serve to facilitate the administration of increased doses of pre-transplantation chemotherapy within the context of moderately intensive conditioning regimens, without excessively compromising procedure-related tolerability. In addition, the advances in our ability to evaluate pretransplant patient comorbidities may help to individualize the dose intensity of regimens accordingly.
Finally, the role of DLI after allogeneic HSCT for CMML has been described by Elliot et al. 11 in 18 patients allografted, using a standard TBI/cyclophosphamide-based regime in 17 and an investigational RIC regimen in 1 patient. Only one patient was in CR at transplantation, with the rest having refractory AML transformed from CMML or persistent/recurrent CMML. Six patients underwent DLI, five for morphological relapse and one for loss of chimerism; two of these patients (one with loss of chimerism and one with morphological relapse) responded to DLI. Similarly, in our cohort, the effects of DLI were seen primarily in patients treated for loss of chimerism (50% response) with no response in patients with morphological disease, suggesting that the graft-versus-CMML effect is either weak or inadequate in the presence of a significant disease burden.
In conclusion, our data support existing evidence that allogeneic HSCT is a feasible therapeutic option for CMML with the ability to attain long-term remission even among subgroups of patients with poor risk disease. Although the use of RIC regimens offers a reduction in transplant-related morbidity, disease relapse is a significant cause of treatment failure in patients undergoing this conditioning modality. Strategies of improved patient selection and prospective studies on the role of dose intensity in CMML are warranted. In light of the recent emergence of novel targeted therapeutic agents in the treatment of this disease, future studies are awaited to assess their potential role in the setting of post-transplant maintenance with or without DLI.
